LMR Partners’s Apellis Pharmaceuticals APLS Stock Holding History

LMR Partners’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-40,000	Closed	-$1M	–	1449
2025 Q4	$1M	Hold	40,000	–	–	﹤0.01%	983
2025 Q3	$905K	Hold	40,000	–	–	﹤0.01%	963
2025 Q2	$692K	Buy	+40,000	New	+$740K	0.01%	874
2024 Q1	–	Sell	-46,700	Closed	-$2.8M	–	1147
2023 Q4	$2.8M	Sell	46,700 -135,400	-74%	-$6.87M	0.03%	419
2023 Q3	$6.93M	Buy	182,100 +180,100	+9,005%	+$7.91M	0.08%	220
2023 Q2	$182K	Buy	+2,000	New	+$173K	﹤0.01%	589

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

LMR Partners's APLS Position: Q2 2026 in Review

LMR Partners sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 403,622 shares — an estimated $16.2M sold.

LMR Partners first reported a position in APLS in Q3 2021 and held it in 7 quarters. The position peaked at $16.2M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

LMR Partners reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
LMR Partners sold 403,622 Apellis Pharmaceuticals shares in Q2 2026, an estimated $16.2M.
LMR Partners first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 7 quarters.
LMR Partners's Apellis Pharmaceuticals position peaked at $16.2M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.